Arrowhead Pharma (ARWR) Stock Price, Quote & News

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, t...

Industry: Biotechnology

Sector: Healthcare

Phone: 626 304 3400

Fax: 626 304 3401

Website: arrowheadpharma.com

Address:

177 East Colorado Boulevard, Suite 700, Pasadena, United States

SBL71 Apr. 17 at 8:05 PM

$ARWR well, some of my shares will be called away...who knew..lol...thanks for the premiums and buying in 2017 so no tears...:) on to $100--SOMEDAY, unless Mani has his way, then we will be $40 or whatever he says the "value" of ARWR is...

0 · Reply

skeezbag Apr. 17 at 12:36 PM

$ARWR 83% of yesterdays volume was short interest. Market is not real $70 Toll booth not paid yet because it's a round number and market maker hasn't positioned their book yet for it to profit first

0 · Reply

skeezbag Apr. 16 at 6:54 PM

$ARWR thank God the market maker was allowed to dictate price to roll their options today and tomorrow at a profit Of course they will say it's not a profit it's to maintain risk and hedge

1 · Reply

lanahx8 Apr. 16 at 6:32 PM

$ARWR biotech setup, needs volume confirmation

0 · Reply

Following_the_trend Apr. 16 at 4:14 PM

$ARWR A bit of a low volume pullback today. I may add.

0 · Reply

johnnygogogo Apr. 16 at 3:42 PM

$ARWR ok, so here’s @CDMO @skeezbag and me performing our theme song: https://m.youtube.com/watch?v=uY4cVhXxW64

2 · Reply

skeezbag Apr. 16 at 2:41 PM

$ARWR 20 more minutes

0 · Reply

CDMO Apr. 16 at 2:12 PM

$ARWR these bot post are dumb af. Thats the future folks. Dead internet. Only me johnny and skeezbag are real

1 · Reply

Scioto Apr. 16 at 2:05 PM

$ARWR what is $ARWR current relationship with $SRPT?

2 · Reply

Scioto Apr. 16 at 2:04 PM

What is $SRPT current relationship with $ARWR?

1 · Reply

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo

Feb 24, 2026, 7:30 AM EST - 7 weeks ago

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

Feb 5, 2026, 4:05 PM EST - 2 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

Feb 4, 2026, 6:15 PM EST - 2 months ago

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

ADT CIEN DAY DVAX OSW

Jan 27, 2026, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Jan 20, 2026, 4:30 PM EST - 3 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Jan 7, 2026, 11:05 PM EST - 3 months ago

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Jan 7, 2026, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Jan 6, 2026, 6:14 PM EST - 3 months ago

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Jan 6, 2026, 11:26 AM EST - 3 months ago

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.

Jan 6, 2026, 10:32 AM EST - 3 months ago

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Jan 6, 2026, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Jan 5, 2026, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Dec 23, 2025, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Dec 15, 2025, 4:30 PM EST - 4 months ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Dec 8, 2025, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Dec 2, 2025, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Dec 1, 2025, 4:00 PM EST - 4 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Nov 25, 2025, 4:00 PM EST - 5 months ago

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Nov 24, 2025, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

SRPT

Nov 18, 2025, 11:52 AM EST - 5 months ago

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Nov 18, 2025, 11:21 AM EST - 5 months ago

US FDA approves Arrowhead's genetic disorder drug

Nov 6, 2025, 4:30 PM EST - 5 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Nov 4, 2025, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Oct 21, 2025, 7:30 AM EDT - 6 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Oct 7, 2025, 7:30 AM EDT - 6 months ago

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Sep 29, 2025, 7:11 AM EDT - 7 months ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ASMB ATRA CORT

Sep 11, 2025, 7:30 AM EDT - 7 months ago

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Sep 10, 2025, 7:30 AM EDT - 7 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Sep 2, 2025, 8:13 AM EDT - 8 months ago

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

NVS

Sep 2, 2025, 7:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Aug 27, 2025, 7:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Aug 13, 2025, 4:10 PM EDT - 8 months ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Aug 7, 2025, 4:01 PM EDT - 9 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Aug 1, 2025, 6:30 AM EDT - 9 months ago

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Jul 28, 2025, 7:30 AM EDT - 9 months ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

SRPT

Jul 23, 2025, 8:00 AM EDT - 9 months ago

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Jul 21, 2025, 4:01 PM EDT - 9 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Jul 8, 2025, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Jun 23, 2025, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jun 4, 2025, 8:02 AM EDT - 11 months ago

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Jun 2, 2025, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

May 29, 2025, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

May 12, 2025, 4:01 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

May 7, 2025, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

Apr 30, 2025, 4:01 PM EDT - 1 year ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Apr 15, 2025, 4:00 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Mar 10, 2025, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Mar 6, 2025, 8:45 AM EST - 1 year ago

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Feb 28, 2025, 9:00 AM EST - 1 year ago

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

SBL71 Apr. 17 at 8:05 PM

0 · Reply

skeezbag Apr. 17 at 12:36 PM

$ARWR 83% of yesterdays volume was short interest. Market is not real $70 Toll booth not paid yet because it's a round number and market maker hasn't positioned their book yet for it to profit first

0 · Reply

skeezbag Apr. 16 at 6:54 PM

$ARWR thank God the market maker was allowed to dictate price to roll their options today and tomorrow at a profit Of course they will say it's not a profit it's to maintain risk and hedge

1 · Reply

lanahx8 Apr. 16 at 6:32 PM

$ARWR biotech setup, needs volume confirmation

0 · Reply

Following_the_trend Apr. 16 at 4:14 PM

$ARWR A bit of a low volume pullback today. I may add.

0 · Reply

johnnygogogo Apr. 16 at 3:42 PM

$ARWR ok, so here’s @CDMO @skeezbag and me performing our theme song: https://m.youtube.com/watch?v=uY4cVhXxW64

2 · Reply

skeezbag Apr. 16 at 2:41 PM

$ARWR 20 more minutes

0 · Reply

CDMO Apr. 16 at 2:12 PM

$ARWR these bot post are dumb af. Thats the future folks. Dead internet. Only me johnny and skeezbag are real

1 · Reply

Scioto Apr. 16 at 2:05 PM

$ARWR what is $ARWR current relationship with $SRPT?

2 · Reply

Scioto Apr. 16 at 2:04 PM

What is $SRPT current relationship with $ARWR?

1 · Reply

Lolobel Apr. 16 at 1:31 PM

$ARWR 🚀🚀🚀

0 · Reply

johnnygogogo Apr. 16 at 1:27 PM

$ARWR from 12 to 6 overnight in the Super XBI Grand Prix

1 · Reply

RebelWarrior1962 Apr. 16 at 11:23 AM

$ARWR

0 · Reply

sque Apr. 16 at 9:56 AM

$ARWR Squeeze squeeze season FOMO penny season Big squeeze starting from here Target 🎯 $30.00

0 · Reply

ArbVinnie Apr. 16 at 9:23 AM

$ARWR up 10% in a couple of days, interesting move

0 · Reply

skeezbag Apr. 15 at 8:00 PM

$ARWR looks like gamma finally flipped on those controlling price Fuck em

1 · Reply

Lolobel Apr. 15 at 8:00 PM

$ARWR something cooking

0 · Reply

Lolobel Apr. 15 at 7:33 PM

$ARWR 🚀

0 · Reply

SBL71 Apr. 15 at 6:28 PM

$ARWR doubt this is “retail Bill” making some buys. Someone is coming in or adding

1 · Reply

CDMO Apr. 15 at 5:54 PM

$ARWR nice price actionnnn

0 · Reply

skeezbag Apr. 15 at 3:10 PM

$ARWR don't forget it's now 11am

1 · Reply

sque Apr. 15 at 2:36 PM

$ARWR Now I go over to c3.ai Penny season FOMO squeeze 🚀 See you all $30.00 Let join us 💪 please

0 · Reply

Market Cap	9.73B
Revenue (ttm)	829.45M
Net Income (ttm)	-1.63M
EPS (ttm)	N/A
PE Ratio	44.43
Forward PE	N/A
Profit Margin	-0.20%
Debt to Equity Ratio	0.36

Volume	4,332,000
Avg Vol	2,822,664
Day's Range	N/A - N/A
Shares Out	140.03M
Stochastic %K	79%
Beta	1.26
Analysts	Strong Sell
Price Target	$81.67